EQL Pharma has entered into an exclusive out-licensing agreement with a leading European Company in ADHD for EQL's proprietary product Mellozzan (melatonin) for Germany, the United Kingdom, Austria, Switzerland, Finland, Denmark and Norway. The agreement applies to tablets in six different strengths as well as an oral solution, where the latter is newly developed and ready to be sent to authorities for registration. Mellozzan is a medicine given to children with sleep disorders who have ADHD and where sleep hygiene measures are not enough.

It can also be given as a short-term treatment to adults with sleep disorders caused by jet lag. Mellozzan was launched by EQL in Sweden in 2021, and EQL's ambition is to offer the product to all other interesting markets in Europe via out-licensing. The agreement includes close to EUR 500,000 in down payment and regulatory milestones.

The royalty on sales is well into the double-digit domain. The launch of Mellozzan will take place over a period of one to three years from today's date, mainly governed by differences in processing times at different countries' authorities for registration and reimbursement. EQL Pharma has advanced negotiations regarding Mellozzan with other companies for additional countries in and outside of Europe.